AbbVie Apogee Deal Highlights Decade of Pharma M&A

AbbVie has reached an agreement to acquire Apogee Therapeutics for $10.9 billion in cash to strengthen its immunology pipeline. This transaction joins a significant list of high-value pharmaceutical mergers and acquisitions over the past decade targeting oncology, neurology, and rare diseases.

Xurve View
洞察:
U.S. flag and medicines are seen in this illustration taken, June 27, 2024. REUTERS/Dado Ruvic/Illustration

ABBVIE INC agreed to acquire APOGEE THERAPEUTICS INC for $10.9 billion in cash midday June 22. The deal targets next-generation immunology treatments to bolster the drugmaker's pipeline. This acquisition marks the latest in a decade-long wave of multi-billion dollar consolidations within the United States pharmaceutical sector.